TY - JOUR

T1 - Prostate cancer surface targets for car T cell therapy or metastatic prostate cancer in the car T cell era

T2 - My kingdom for the target!

AU - Kulemzin, Sergey V.

AU - Gorchakov, Andrey A.

AU - Taranin, Aleksandr V.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Despite the progress achieved in target, chemo-, and radiotherapy, treatment options for patients with latestage metastatic castration-resistant prostate cancer are presently very limited. Use of dendritic cell-based vaccines exemplified by sipuleucel-T appears is rarely curative and is effective in only a fraction of such patients. Given the success of CAR T cell therapy in the field of B cell malignancies, significant efforts have been made to adapt this powerful technology to the problem of metastatic prostate cancer. Availability of unique prostate cancer surface targets for CAR T cells has thereby become a pressing issue in the field of CAR design. Ideally, such targets should be absent from normal cells or tissues, be present on all prostate cancer cells across all patients, and be indispensable for the survival of cancer cells. In reality, however, none of the prostate cancer-associated surface markers described to date are matching such description. Here, we catalogue the list of tested as well as prospective surface antigens to be used as targets for CAR T cell therapy, and discuss the aspects of their safety and potential efficacy.

AB - Despite the progress achieved in target, chemo-, and radiotherapy, treatment options for patients with latestage metastatic castration-resistant prostate cancer are presently very limited. Use of dendritic cell-based vaccines exemplified by sipuleucel-T appears is rarely curative and is effective in only a fraction of such patients. Given the success of CAR T cell therapy in the field of B cell malignancies, significant efforts have been made to adapt this powerful technology to the problem of metastatic prostate cancer. Availability of unique prostate cancer surface targets for CAR T cells has thereby become a pressing issue in the field of CAR design. Ideally, such targets should be absent from normal cells or tissues, be present on all prostate cancer cells across all patients, and be indispensable for the survival of cancer cells. In reality, however, none of the prostate cancer-associated surface markers described to date are matching such description. Here, we catalogue the list of tested as well as prospective surface antigens to be used as targets for CAR T cell therapy, and discuss the aspects of their safety and potential efficacy.

KW - CAR T cells

KW - Chimeric antigen receptor

KW - Immunotherapy

KW - Metastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85078980119&partnerID=8YFLogxK

U2 - 10.18620/ctt-1866-8836-2019-8-4-19-28

DO - 10.18620/ctt-1866-8836-2019-8-4-19-28

M3 - Review article

AN - SCOPUS:85078980119

VL - 8

SP - 19

EP - 28

JO - Cellular Therapy and Transplantation

JF - Cellular Therapy and Transplantation

SN - 1867-416X

IS - 4

ER -